Number of Patients With Dose-limiting Toxicity as a Measure of Safety (Parts 1 and 3) Up to 6 weeks after the last dose [clinicaltrials_resource:1410301ba1d1a684a0c1f814db25474c]
Tumor response will be evaluated as sum of complete response (CR) and partial response (PR). CR is disappearance of all measurable and evaluable disease. No new lesions. No evidence of non evaluable disease. PR is 50% or more decrease from baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable disease. No new lesions.
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]
Number of Patients With Dose-limiting Toxicity as a Measure of Safety (Parts 1 and 3) Up to 6 weeks after the last dose [clinicaltrials_resource:1410301ba1d1a684a0c1f814db25474c]
Tumor response will be evaluated as sum of complete response (CR) and partial response (PR). CR is disappearance of all measurable and evaluable disease. No new lesions. No evidence of non evaluable disease. PR is 50% or more decrease from baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable disease. No new lesions.
Bio2RDF identifier
1410301ba1d1a684a0c1f814db25474c
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:1410301ba1d1a684a0c1f814db25474c
measure [clinicaltrials_vocabulary:measure]
Number of Patients With Dose-limiting Toxicity as a Measure of Safety (Parts 1 and 3)
time frame [clinicaltrials_vocabulary:time-frame]
Up to 6 weeks after the last dose
description
Tumor response will be evaluat ...... uable disease. No new lesions.
identifier
clinicaltrials_resource:1410301ba1d1a684a0c1f814db25474c
title
Number of Patients With Dose-l ...... to 6 weeks after the last dose
@en
type
label
Number of Patients With Dose-l ...... 0301ba1d1a684a0c1f814db25474c]
@en